Tear Interleukin Biomarkers After Glaucoma Treatment
ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKazakh Eye Research Institute
About this trial
This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively.
Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.
Eligibility criteria
Qualifiers
Decision to treat by MP-CPC Laser
Patients diagnosed with Glaucoma
Patients aged 18 years old and above
Glaucoma that is inadequately controlled on medical therapy
Disqualifiers
Patients age less than 18 years
Patients unable or unwilling to provide informed consent to participate in the study
Patients potentially unavailable for follow up visits
Patients with significant scleral thinning
Trial design
Treatments tested in this trial
- MicroPulse Transscleral Cyclophotocoagulation
- Conventional Transscleral Cyclophotocoagulation
- Antiglaucoma Surgery
Treatment groups
24 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov